Pasireotide injection (Signifor®)

Pasireotide (Signifor) is covered for adults (≥18) with Cushing's disease who are not surgical candidates or whose surgery was not curative, and for adults with endogenous Cushing's syndrome awaiting surgery or awaiting radiotherapy response, and is excluded for patients under 18 or those eligible for curative pituitary surgery. Coverage requires prescribing by or consultation with an endocrinologist/specialist, documentation of surgical ineligibility or awaiting surgery/radiotherapy response, initial approval typically for 4 months (reauthorization 12 months for responders), documented clinical response for reauthorization, and a reduced starting dose for Child‑Pugh B hepatic impairment.

"Treatment of adult individuals with Cushing's disease for whom pituitary surgery is not an option or has not been curative."

Sign up to see full coverage criteria, indications, and limitations.